Olympus Corporation

Guidance & outlook revised down (mix of one-offs + execution): Revenue guidance on a constant-currency basis was revised down ~2%. Management attributed much of the pressure to SIS ship holds/recalls (described as “unfortunate” but primarily one-off), plus smaller ship holds in GI. The company said its mid-term destination is unchanged: remain a mid-single-digit revenue growth player and reach 20%+ operating margin (no reset of the 3/4/5 plan).

Q3 weakness was mainly U.S. commercial execution in GI (not lost competitiveness): For GI in the U.S., management explicitly said they were not satisfied with Q3 performance, and that it’s not due to declining product competitiveness/clinician preference. The problem was pipeline conversion / commercial execution: they had a pipeline that didn’t convert. Confidence for Q4 is tied to tighter discipline and pipeline management (they referenced tightening go-to-market execution in China using weekly oversight calls as an example; China moved from sustained underperformance toward ~+6% growth in Q3 after prior double-digit decline).

Q4 confidence + ranges for transparency (ship holds expected to resolve): The company now guides with ranges, stating ranges reflect timing/dynamic market effects rather than lower confidence. They do not expect additional ship holds, but expect ship-hold product releases into Q4, meaning sales timing could be higher/lower depending on release dates. (So the “range” is essentially about when products come back, not whether.)